Global Disseminated Intravascular Coagulation Diagnosis Market - 2022-2029

Global Disseminated Intravascular Coagulation Diagnosis Market - 2022-2029

Market Overview

The global disseminated intravascular coagulation diagnosis market is expected to grow at a CAGR of 3% during the forecast period (2022-2029).

Disseminated intravascular coagulation (DIC) is a rare but severe blood clotting disorder. It's a clotting problem that can lead to uncontrollable bleeding. People with cancer or sepsis may be affected by DIC.

Market Dynamics

The increasing research and development and the growing prevalence of disseminated intravascular coagulation disorder are factors influencing the global disseminated intravascular coagulation diagnosis market.

The increasing research and development are expected to drive the market growth in the forecast period

DIC is an acquired clinic biological syndrome characterized by widespread coagulation activation, which results in fibrin deposition in the vasculature, organ dysfunction, clotting factor and platelet consumption, and life-threatening hemorrhage. Several underlying disorders can cause disseminated intravascular coagulation (sepsis, cancer, trauma, and pregnancy complicated with eclampsia or other calamities). The cornerstone therapeutic approaches are treating the underlying disease and eliminating the trigger mechanism. DIC-specific therapeutic strategies aim to reduce blood coagulation activation and bleeding risk. Few clinical trials use DIC as an entry criterion.

Moreover, in patients with sepsis, the risk of DIC is especially high. Indeed, DIC affects 30 to 50 percent of them, whereas DIC affects only about ten percent of patients with solid tumors, trauma, or obstetric emergencies. Because established clinical scoring systems for DIC are not systematically used in clinical practice, the overall prevalence of DIC in hospitalized patients is unknown. Furthermore, the prevalence of DIC varies by hospitalization setting and is higher in critically ill patients admitted to intensive care units (ICUs). DIC prevalence in this subset of patients varies between 8.5 percent and 34 percent, depending on the underlying diagnoses and the diagnostic scoring system used.

Limitations associated with disseminated intravascular coagulation are expected to hamper the market growth

The patient may be prescribed anticoagulant medication or blood thinners if they have disseminated intravascular coagulation (DIC) to prevent blood clots. Internal bleeding, for instance, is a common side effect. Antifibrinolytic agents (e.g., tranexamic acid, -aminocaproic acid) should be avoided in DIC because they have been linked to thrombotic complications such as myocardial infarction and renal artery thrombosis when systemic clotting is present. Patients with DIC should be treated in hospitals specializing in critical care and subspecialty care, such as hematology, blood banking, or surgery. Patients who present to hospitals without those capabilities and are stable enough to be transferred should be quickly referred to a facility that does.

COVID-19 Impact Analysis

A coagulopathy that appears to be linked to venous and arterial thromboembolic disease is one of the major complications of severe COVID-19 infections. The coagulation changes are like disseminated intravascular coagulation but not identical (DIC). Most COVID-19 patients do not meet the criteria for traditional DIC. Furthermore, the coagulopathic response to severe COVID-19 appears to be influenced by features of a strong local pulmonary thrombotic microangiopathy and direct endothelial cell infection and injury by the virus. COVID-19 appears to cause a distinct intravascular coagulation syndrome with its diagnostic criteria.

Segment Analysis

D-dimer segment is expected to dominate the market growth

The diagnosis of disseminated intravascular coagulation (DIC) can be challenging, especially in chronic, smoldering DIC with subtle clinical and laboratory abnormalities. Although no single routinely available laboratory test is sensitive or specific enough to diagnose DIC, several commonly available laboratory tests frequently yield abnormal results in DIC. The presence of moderate-to-severe thrombocytopenia is common. For DIC, the D-dimer test is preferable. As a result, testing for D-dimer or FDPs may be useful in distinguishing DIC from other conditions that cause low platelet counts and long clotting times, such as chronic liver disease. The D-dimer test is available in most laboratories. For the diagnosis of acute DIC, the D-dimer test was found to be highly specific but less sensitive. The cross-linked fibrin degradation fragment D-dimer in patients at risk of DIC is strong evidence for the diagnosis. The presence of D-dimer indicates that both thrombin and plasmin have been produced.

Geographical Analysis

North America region is expected to hold the largest market share in the global disseminated intravascular coagulation diagnosis market

The region's rising healthcare spending and adoption of advanced technologies Furthermore, there is an increasing demand for advanced treatment options for this disease. The presence of key players in this region is expected to drive market growth. For instance, AdvaCare, an American company, manufactures the D-Dimer Test Kit designed to assess circulating derivatives of cross-linked degradation products (XL-FDP) in human plasma, whole blood, EDTA blood, and citrated blood using colour development in the test kit. The D-Dimer test kit was developed specifically to diagnose disseminated intravascular coagulation. It can be determined through a blood test to aid in the successful diagnosis of Thrombosis.

Competitive Landscape

The Global Disseminated Intravascular Coagulation Diagnosis Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Abbott, AdvaCare Pharma, Axis-Shield Diagnostics Ltd, Eurolyser Diagnostica GmbH, Quidel Corporation, CTK Biotech, Inc., AccuBioTech Co., Ltd., Getein Biotech, Inc., Siemens Healthcare GmbH, PHC Corporation

AdvaCare Pharma

Overview: AdvaCare Pharma is a global pharmaceutical, antimalarial, oncology, supplement, veterinary product, and medical device manufacturer serving over 65 countries. The company's products have received GMP, CE, ISO, and USFDA certifications. It was founded in 2007.

Product Portfolio: The D-Dimer Test Kit is designed to assess circulating derivatives of cross-linked degradation products (XL-FDP) in human plasma, whole blood, EDTA blood, and citrated blood using colour development in the test kit. The D-Dimer test kit was developed specifically to diagnose disseminated intravascular coagulation.

Why Purchase the Report?
• Visualize the composition of the global disseminated intravascular coagulation diagnosis market segmentation by diagnosis and end-users highlighting the key commercial assets and players.
• Identify commercial opportunities in global disseminated intravascular coagulation diagnosis market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of global disseminated intravascular coagulation diagnosis market- level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global disseminated intravascular coagulation diagnosis market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers